颅内生殖细胞瘤综合治疗

报告５０例颅内生殖细胞瘤，手术治疗１９例，放射治疗４３例。综合治疗后临床症状改善４１例，无效２例。随访３２例，其中恢复正常工作或学习者１４例，生活能自理１２例，生活部分需人帮助４例，死亡２例。５年生存率为５０％。推荐放疗为首选治疗手段，并对合并颅内压增高及多发性、复发性肿瘤的治疗作了讨论。     

放疗同期卡莫氟化疗治疗局部中晚期鼻咽癌的Ⅲ期临床观察

目的:探讨患者对联合应用诱导化疗和放疗同期口服卡莫氟治疗局部中晚期鼻咽癌疗效和不良反应.方法:收治66例局部中晚期鼻咽癌患者,随机分为两组,诱导化疗随后放疗组简称为对照纽,诱导化疗随后放疗同期卡莫氟治疗组简称为治疗组.两组患者数均为33例.进行根治性放疗前两组患者均接受两个疗程诱导化疗.治疗组在放疗期间同时口服卡莫氟.结果:诱导化疗有效率高,平均有效率高达87%,其中平均完全缓解率(CR)为8.7%、不完全缓解率(PR)为78.4%.对照组鼻咽肿瘤、颈部转移淋巴结全消平均剂量均高于治疗组,统计学有差异.放疗后3个月治疗组鼻咽、颈部转移淋巴结CR均高于对照组(p=0.016,P=0.042).随访期内治疗组患者局部复发率和远处转移率有降低趋势.临床治疗中出现的主要毒副反应为白细胞下降、口腔粘膜炎、急性放射性皮炎及由卡莫氟引起的热感、尿频、头昏等.结论:放疗同期口服卡莫氟治疗局部中晚期鼻咽癌,降低了鼻咽和颈部肿瘤完全消退的照射剂量,提高了鼻咽肿瘤和颈部转移灶的完全缓解率,局部复发率和远处转移率有下降趋势.尽管加卡莫氟患者毒的副作用加重,但可以耐受,经对症处理绝大部分患者能按计划完成治疗.在鼻咽癌同步化放疗方案中卡莫氟的推荐剂量为600mg/d,分3次口服.放疗同期口服卡莫氟治疗的远期疗效有待于进一步观察.     

颌面颈部恶性淋巴瘤临床分析

目的：总结口腔颌面颈部恶性淋巴瘤(ML)的诊断方法及治疗措施。方法：回顾性分析收治的ML患者38例的临床资料。结果：霍奇金病(HD)5例，非霍奇金淋巴瘤(NHL)33例，31例采用综合治疗，7例采用单纯化疗，38例1，3，5a生存者分别为5，14，12例，存活患者中以临床Ⅰ，Ⅱ期者占绝大多数，死亡患者中以Ⅳ期为多。结论：早期明确ML的诊断并早期治疗效果较好，综合治疗是最有效的治疗手段，临床分期对预后有重要参考价值。     

关于放射治疗科室的组建

论述了医院组建放射治疗科室进行可行性分析时应考虑的因素,从技术设施、诊疗室与住院病房等方面介绍了放射治疗科的基本组建要求。     

肛管鳞癌的诊断与治疗(附15例分析)

目的探讨肛管癌诊断、治疗和预后的相关因素。方法北京医院1984-1998年间收治15例肛管鳞癌,首次诊断为肛管癌者仅5例。15例中行放疗化疗11例,8例行Miles手术。结果病理均证实为鳞癌。根据NCCN(2003年)分期,Ⅰ期6例,Ⅱ期4例,ⅢA期2例,ⅢB期3例。免疫组织化学染色显示肿瘤组织间质纤维化(+++)者4例,(++)者7例,(+)者4例。随诊最长10年,平均生存期(47±27.6)个月。结论肛门指诊是发现和诊断肛管癌的重要手段。放疗以及以放疗为主,化疗、手术为辅的综合治疗是肛管癌的主要治疗方法。肿瘤分期、腹股沟淋巴结转移、治疗方法以及肿瘤组织间质纤维化对病人的预后均有影响。     

Postoperative radiotherapy for locally advanced colon cancer

Background: The role of adjuvant postoperative radiotherapy for locally advanced colon cancer is not well documented. Methods: Seventy-eight patients who underwent a complete resection of B2-C colon cancer received postoperative radiotherapy. Twenty-eight patients received ⩽45 Gy; 50 patients received 50–55 Gy. Twenty-seven patients received adjuvant fluorouracil-based chemotherapy. All patients were followed for a minimum of 3 years; no patients were lost to follow-up. Results: The overall local control rate was 88%. The 5-year actuarial rate of local control was 96% after 50–55 Gy postoperative radiotherapy compared with 76% after <50 Gy (p=0.0095). Multivariate analysis of local control showed that only radiotherapy dose significantly influenced this end point. Cause-specific survival rates at 5 years were B2, 67%; B3, 90%; C1, 100%; C2, 61%; C3, 36%; and overall, 63%. Multivariate analysis of cause-specific survival showed that only stage significantly influenced this end point. Bowel obstruction caused by adhesions developed in three patients and required a laparotomy; radiation-induced sarcoma developed in one additional patient. Conclusions: Postoperative radiotherapy appears to reduce the risk of local recurrence in patients with locally advanced colon cancer. The optimal dose is probably 50–55 Gy at 1.8 Gy per fraction. Postoperative radiotherapy may improve cause-specific survival for patients with stages B3 and C2 cancers.     

全脑全脊髓照射仰卧位CT模拟定位技术

目的：探讨全脑全脊髓照射仰卧位CT模拟定位技术。方法：7名患者分别躺在真空负压袋固定器上，进行CT模拟定位，打印正侧位数字重建射线彩像（DRR）图，放射治疗前拍摄正侧位定位验证片，测量解剖参考点和射野边界之间的距离。结果：患者左右方向及背腹方向误差在2mm以内。人体上下方向误差在4mm以内；放疗后，患者受照射的皮肤部位均出现色素沉着。结论：仰卧位全脑全脊髓照射CT模拟定位技术可用于俯卧位不合作的患者。     

高能重带电粒子束平均能量计算的一个简单公式

本文提出了一个计算高能重带电粒子束平衡能量的简单公式。在计算重带电粒子放射治疗剂量时，用此公式可获得与平均能量有关的物理量的解析表达式，用此公式计算了入射铝内10-MeV的质子束的平均能量，并与相应的实验数据作了比较，比较表明，本文提出的公式在相当大的能量范围内能够精确地预言重带电粒子的平均能量，此外，还计算了在水中在100-MeV、150-MeV和200-MeV的质子束的平均能量。     

放疗计划系统网络体系的设计与实现

设计并建立一套连接医学影像采集设备(如CTM、RIP、ET等)、放疗计划系统(TPS)及医用加速器等大型设备的的放射治疗网络体系工作环境,更充分地发挥局域网络在放射治疗中的作用。在现有大型医疗设备、TPS及局域网环境的基础上,提出两种具有代表性的TPS网络体系解决方案,并结合各自的特点及实际应用情况对其进行了分析和比较。实践证明,放疗计划系统网络体系的建设推进了放射治疗全过程的数字化、网络化,在更大范围内实现了医疗信息资源的共享,在更大程度上发挥了TPS在肿瘤治疗过程中的作用。     

Chemotherapie mit Cisplatin-Bleomycin und nachfolgende Strahlentherapie bei fortgeschrittenen Kopf-Hals-Tumoren

Summary 42 patients with advanced stage III and IV squamous cell carcinoma of the head and neck were treated with initial cisplatin and bleomycin chemotherapy and subsequent radiotherapy. 39 were evaluable for results, and 3 for toxicity only. 8 patients suffered from stage III and 31 from stage IV tumors, of these 10 with distant metastases. 5 patients underwent later a rescue operation. 27 were previously untreated (= group A) including 2 cases with localized relapses beyond the margins of surgical and/or radiotherapeutic treatment fields. 12 patients had a recurrence within pretreated areas (= group B). The induction chemotherapy alone showed the following results: In group A 4 (15%) CR, 10 (37%) PR, 7 (26%) MR; in group B 3 (25%) PR, 2 (17%) MR. The subsequent radiotherapy mostly consisted of a 65 Gy tumor dose given in 61/2 weeks. The results after completion of the combined modality therapy were: In group A 44% CR, 28% PR; in group B 10% CR and 30% PR. No patient resistant to the initial chemotherapy responded to the radiotherapy. The median survival time of stage III patients was 20 months but only 7 months in stage IV patients. 4 of all live with NED now between 30+ and 41+ months; 1 patient is alive with relapse. All the others are dead after a survival time of max. 32 months, included the 5 with rescue operation. In general, hematologic and renal toxicities were not severe, but nausea and vomiting were the worst tolerated side effects. 1 patient died from septic myocarditis having a WBC nadir of 2000/µl, probably due to additional immunologic deficiency because of inactive liver cirrhosis. The poor results concerning NED survival are discussed. We conclude, that an initial chemotherapy with CDDP and BLM gives good remission effects but its combination with radiotherapy at present fails to produce a NED survival benefit. Further efforts are necessary to improve the CR and the long time survivor rates.

Die Autoren danken folgenden Kollegen für ihre Mitarbeit: Drs. Garbea (HNO), B. Bienko, M. Danker, N. Birke, M. Klessing, K. Lottner, W. Palm